Download
00432_2024_Article_5699.pdf 692,83KB
WeightNameValue
1000 Titel
  • Prognostic impact of metabolic syndrome in patients with primary endometrial cancer: a retrospective bicentric study
1000 Autor/in
  1. Shehaj, Ina |
  2. Krajnak, Slavomir |
  3. Rad, Morva Tahmasbi |
  4. Gasimli, Bahar |
  5. Hasenburg, Annette |
  6. Karn, Thomas |
  7. Schmidt, Marcus |
  8. Müller, Volker |
  9. Becker, Sven |
  10. Gasimli, Khayal |
1000 Verlag Springer Berlin Heidelberg
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-04-03
1000 Erschienen in
1000 Quellenangabe
  • 150(4):174
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00432-024-05699-1 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10991018/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:sec> <jats:title>Purpose</jats:title> <jats:p>Endometrial cancer (EC) is the most common gynaecological cancer. Its incidence has been rising over the years with ageing and increased obesity of the high-income countries’ populations. Metabolic syndrome (MetS) has been suggested to be associated with EC. The aim of this study was to assess whether MetS has a significant impact on oncological outcome in patients with EC.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>This retrospective study included patients treated for EC between January 2010 and December 2020 in two referral oncological centers. Obesity, arterial hypertension (AH) and diabetes mellitus (DM) were criteria for the definition of MetS. The impact of MetS on progression free survival (PFS) and overall survival (OS) was assessed with log-rank test and Cox regression analyses.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>Among the 415 patients with a median age of 64, 38 (9.2%) fulfilled the criteria for MetS. The median follow-up time was 43 months.</jats:p> <jats:p>Patients suffering from MetS did not show any significant differences regarding PFS (36.0 vs. 40.0 months, HR: 1.49, 95% CI 0.79–2.80 P = 0.210) and OS (38.0 vs. 43.0 months, HR: 1.66, 95% CI 0.97–2.87, P = 0.063) compared to patients without MetS. Patients with obesity alone had a significantly shorter median PFS compared to patients without obesity (34.5 vs. 44.0 months, P = 0.029). AH and DM separately had no significant impact on PFS or OS (p &gt; 0.05).</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>In our analysis, MetS in patients with EC was not associated with impaired oncological outcome. However, our findings show that obesity itself is an important comorbidity associated with significantly reduced PFS.</jats:p> </jats:sec>
1000 Sacherschließung
lokal Obesity
lokal Female [MeSH]
lokal Metabolic Syndrome/epidemiology [MeSH]
lokal Humans [MeSH]
lokal Endometrial cancer
lokal Retrospective Studies [MeSH]
lokal Obesity/complications [MeSH]
lokal Endometrial Neoplasms/complications [MeSH]
lokal Survival
lokal Metabolic syndrome
lokal Research
lokal Prognosis [MeSH]
lokal Endometrial Neoplasms/therapy [MeSH]
lokal Metabolic Syndrome/complications [MeSH]
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0009-0001-3304-5040|https://frl.publisso.de/adhoc/uri/S3Jham5haywgU2xhdm9taXI=|https://frl.publisso.de/adhoc/uri/UmFkLCBNb3J2YSBUYWhtYXNiaQ==|https://frl.publisso.de/adhoc/uri/R2FzaW1saSwgQmFoYXI=|https://frl.publisso.de/adhoc/uri/SGFzZW5idXJnLCBBbm5ldHRl|https://frl.publisso.de/adhoc/uri/S2FybiwgVGhvbWFz|https://frl.publisso.de/adhoc/uri/U2NobWlkdCwgTWFyY3Vz|https://frl.publisso.de/adhoc/uri/TcO8bGxlciwgVm9sa2Vy|https://frl.publisso.de/adhoc/uri/QmVja2VyLCBTdmVu|https://frl.publisso.de/adhoc/uri/R2FzaW1saSwgS2hheWFs
1000 Hinweis
  • DeepGreen-ID: a92e615da3e44eebbe7cf3691683a428 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Universitätsmedizin der Johannes Gutenberg-Universität Mainz |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Universitätsmedizin der Johannes Gutenberg-Universität Mainz |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6507150.rdf
1000 Erstellt am 2025-02-06T13:29:05.966+0100
1000 Erstellt von 322
1000 beschreibt frl:6507150
1000 Zuletzt bearbeitet 2025-09-14T08:29:17.259+0200
1000 Objekt bearb. Sun Sep 14 08:29:17 CEST 2025
1000 Vgl. frl:6507150
1000 Oai Id
  1. oai:frl.publisso.de:frl:6507150 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source